Thermo Fisher Scientific FGF23 Polyclonal Antibody, PeproTech

Applications

Western Blot (WB)

• Tested Dilution: 0.1–0.2 µg/mL

ELISA

• Tested Dilution: 0.5–2.0 µg/mL

Product Specifications

Product Specific Information

AA Sequence of recombinant protein:
MYPNASPLLG SSWGGLIHLY TATARNSYHL QIHKNGHVDG APHQTIYSAL MIRSEDAGFV VITGVMSRRY LCMDFRGNIF GSHYFDPENC RFQHQTLENG YDVYHSPQYH FLVSLGRAKR AFLPGMNPPP YSQFLSRRNE IPLIHFNTPI PRRHTRSAED DSERDPLNVL KPRARMTPAP ASCSQELPSA EDNSPMASDP LGVVRGGRVN THAGGTGPEG CRPFAKFI

Preparation:
Produced from sera of rabbits immunized with highly pure Recombinant Human FGF-23. Anti-Human FGF-23-specific antibody was purified by affinity chromatography employing an immobilized Human FGF-23 matrix.

Sandwich ELISA:
To detect Human FGF-23 by sandwich ELISA (using 100 µL/well), a concentration of 0.5–2.0 µg/mL of this antibody is required. When used with PeproTech Biotinylated Anti-Human FGF-23 (500-P319BT) as a detection antibody, allows detection of at least 2000–4000 pg/mL of Recombinant Human FGF-23.

Western Blot:
To detect Human FGF-23 by Western Blot analysis, use at a concentration of 0.1–0.2 µg/mL. Detection limit for Recombinant Human FGF-23 is 1.5–3.0 ng/lane under reducing or non-reducing conditions.

Target Information

The protein encoded by this gene is a member of the fibroblast growth factor family. FGF family members possess broad mitogenic and cell survival activities and are involved in biological processes such as embryonic development, cell growth, morphogenesis, tissue repair, tumor growth, and invasion.
FGF23 inhibits renal tubular phosphate transport. Mutations in this gene are associated with autosomal dominant hypophosphatemic rickets and familial tumoral calcinosis with hyperphosphatemia. Abnormally high expression is linked to oncogenic hypophosphatemic osteomalacia.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.